Primary CNS Lymphoma Clinical Trials This is an RSS file. You can use it to subscribe to this data in your favourite RSS reader or to display this data on your own website or blog.

• News
• Research
• Blogs
• Podcasts
• Video
• Clinical Trials

Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL
Condition:   Primary Central Nervous System Lymphoma Interventions:   Drug: Orelabrutinib;   Drug: Pomalidomide;   Drug: Rituximab;   Drug: Methotrexate Sponsors:   Peking Union Medical College Hospital;   Beijing Tiantan Hospital;   Sanbo Brain Hospital Capital Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 25, 2022 Category: Research Source Type: clinical trials

[18F]-Fludarabine PET/MRI in Primary Central Nervous System Lymphoma
Condition:   Primary Central Nervous System Lymphoma Intervention:   Drug: PET-MRI Sponsor:   Assistance Publique - Hôpitaux de Paris Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 25, 2022 Category: Research Source Type: clinical trials

Sequential Treatment With RO-MTX After Pomalidomide, Orelabrutinib, Rituximab (POR) in Newly-diagnosed PCNSL
Condition:   Primary Central Nervous System Lymphoma Interventions:   Drug: Orelabrutinib;   Drug: Pomalidomide;   Drug: Rituximab;   Drug: Methotrexate Sponsors:   Peking Union Medical College Hospital;   Beijing Tiantan Hospital;   Sanbo Brain Hospital Capital Medical University Recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - May 25, 2022 Category: Research Source Type: clinical trials

Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma
Condition:   Primary Central Nervous System Lymphoma Intervention:   Drug: Penpulimab Sponsor:   The First Affiliated Hospital with Nanjing Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2022 Category: Research Source Type: clinical trials

Study of the Pronostic Impact of Immunohistochemical, Histological and Radiological Factors in Patients With Primary Central Nervous System Lymphoma.
Condition:   Rare Disease With Poor Outcome Intervention:   Sponsor:   Central Hospital, Nancy, France Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2022 Category: Research Source Type: clinical trials

Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma
Condition:   Primary Central Nervous System Lymphoma Intervention:   Drug: Penpulimab Sponsor:   The First Affiliated Hospital with Nanjing Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2022 Category: Research Source Type: clinical trials

Study of the Pronostic Impact of Immunohistochemical, Histological and Radiological Factors in Patients With Primary Central Nervous System Lymphoma.
Condition:   Rare Disease With Poor Outcome Intervention:   Sponsor:   Central Hospital, Nancy, France Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2022 Category: Research Source Type: clinical trials

Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma
Condition:   Primary Central Nervous System Lymphoma Intervention:   Drug: Penpulimab Sponsor:   The First Affiliated Hospital with Nanjing Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2022 Category: Research Source Type: clinical trials

Study of the Pronostic Impact of Immunohistochemical, Histological and Radiological Factors in Patients With Primary Central Nervous System Lymphoma.
Condition:   Rare Disease With Poor Outcome Intervention:   Sponsor:   Central Hospital, Nancy, France Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2022 Category: Research Source Type: clinical trials

Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma
Condition:   Primary Central Nervous System Lymphoma Intervention:   Drug: Penpulimab Sponsor:   The First Affiliated Hospital with Nanjing Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2022 Category: Research Source Type: clinical trials

Study of the Pronostic Impact of Immunohistochemical, Histological and Radiological Factors in Patients With Primary Central Nervous System Lymphoma.
Condition:   Rare Disease With Poor Outcome Intervention:   Sponsor:   Central Hospital, Nancy, France Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2022 Category: Research Source Type: clinical trials

Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma
Condition:   Primary Central Nervous System Lymphoma Intervention:   Drug: Penpulimab Sponsor:   The First Affiliated Hospital with Nanjing Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2022 Category: Research Source Type: clinical trials

Study of the Pronostic Impact of Immunohistochemical, Histological and Radiological Factors in Patients With Primary Central Nervous System Lymphoma.
Condition:   Rare Disease With Poor Outcome Intervention:   Sponsor:   Central Hospital, Nancy, France Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2022 Category: Research Source Type: clinical trials

Penpulimab Combined With RMA Treatment of Primary Diagnosis of Primary Central Nervous System Lymphoma
Condition:   Primary Central Nervous System Lymphoma Intervention:   Drug: Penpulimab Sponsor:   The First Affiliated Hospital with Nanjing Medical University Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2022 Category: Research Source Type: clinical trials

Study of the Pronostic Impact of Immunohistochemical, Histological and Radiological Factors in Patients With Primary Central Nervous System Lymphoma.
Condition:   Rare Disease With Poor Outcome Intervention:   Sponsor:   Central Hospital, Nancy, France Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - April 26, 2022 Category: Research Source Type: clinical trials